
Opinion|Videos|December 16, 2024
Managing CRS and ICANS: Approaches and Protocols
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how clinical management of CAR T-cell therapy–associated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms.
Advertisement
Episodes in this series

Video content above is prompted by the following
What is your approach to managing toxicities such as CRS and ICANS?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Capvaxive Expanded Indication to Include Children, Adolescents at Increased Risk for Pneumococcal Disease
2
FDA Clears First Single-Inhaler Triple Therapy for Asthma
3
FDA Clears the Way for First Generic Single-Dose Flu Treatment Ahead of 2026 Season
4
Metformin Cuts Long COVID Risk by 50%, New Trial Confirms
5

















































































































